News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
801,355 Results
Type
Article (68750)
Company Profile (229)
Press Release (732358)
Multimedia
Podcasts (243)
Webinars (41)
Section
Business (244572)
Career Advice (3474)
Deals (37847)
Drug Delivery (230)
Drug Development (87014)
Employer Resources (197)
FDA (17872)
Job Trends (16702)
News (366686)
Policy (36200)
Tag
2025 Best Places to Work (2)
2026 Best Places to Work (2)
2027 BioCapital Elite (1)
2027 BioCapital Standard (5)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (3)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (11)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (8)
2027 Genetown Elite (4)
2027 Genetown Premier (1)
2027 Genetown Standard (12)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (12)
40 Under 40 (2)
Academia (3101)
Academic (1)
Accelerated approval (74)
ADA (53)
Adcomms (44)
Allergies (229)
Alliances (54614)
ALS (284)
Alzheimer's disease (2114)
Antibody-drug conjugate (ADC) (753)
Approvals (18448)
Artificial intelligence (1040)
ASCO (349)
Autoimmune disease (496)
Automation (81)
Bankruptcy (379)
Belgium (35)
Best Places to Work (12473)
BIO (79)
Biologics (88)
BIOSECURE Act (23)
Biosimilars (301)
BioSpace Insights (220)
Biotechnology (152)
Bispecific (45)
Bladder cancer (242)
Brain cancer (99)
Breast cancer (956)
Cancer (7810)
Cardiovascular disease (660)
Career advice (3006)
Career pathing (65)
CAR-T (451)
CDC (81)
CDMO (220)
Celiac Disease (6)
Cell-line development (1)
Cell therapy (1210)
Cervical cancer (66)
Clinical research (77209)
Collaboration (2817)
Commercialization (57)
Company closure (9)
Compensation (1873)
Complete response letters (126)
COVID-19 (3069)
CRISPR (147)
CRO (3)
C-suite (1678)
Cystic fibrosis (182)
Data (10627)
Decentralized trials (4)
Denatured (80)
Depression (222)
Dermatology (189)
Diabetes (830)
Diagnostics (7838)
Digital health (79)
Diversity (13)
Diversity, equity & inclusion (47)
Drug discovery (507)
Drug pricing (251)
Drug shortages (40)
Duchenne muscular dystrophy (380)
Earnings (89335)
Editorial (85)
Employer branding (26)
Employer resources (179)
ESMO (433)
Events (121988)
Executive appointments (1374)
Eye disease (16)
FDA (22839)
Fibrodysplasia Ossificans Progressiva (16)
Fragile X (5)
Friedreich's ataxia (28)
Frontotemporal dementia (42)
Funding (2309)
Gene editing (309)
Generative AI (93)
Gene therapy (950)
GLP-1 (1378)
Government (5465)
Grass and pollen (8)
Guidances (439)
Healthcare (21134)
Hematology (205)
HIV (120)
Huntington's disease (88)
Idiopathic pulmonary fibrosis (14)
IgA nephropathy (154)
Immunology and inflammation (423)
Immuno-oncology (159)
Indications (287)
Infectious disease (3519)
Inflammatory bowel disease (276)
Inflation Reduction Act (16)
Influenza (162)
Intellectual property (377)
Interviews (675)
IPO (17451)
IRA (60)
Job creations (4468)
Job search strategy (2407)
JPM (73)
Kidney cancer (31)
Kidney disease (168)
Labor market (135)
Layoffs (718)
Leadership (68)
Legal (8862)
Licensing (99)
Liver cancer (119)
Longevity (55)
Lung cancer (1083)
Lung diease (22)
Lymphoma (545)
Machine learning (76)
Management (71)
Manufacturing (1587)
Marketing (33)
MASH (248)
Medical affairs (5)
Medical device (15211)
Medtech (15524)
Mergers & acquisitions (21938)
Metabolic disorders (2096)
mRNA (331)
Multiple sclerosis (253)
Multispecific (6)
NASH (24)
Netherlands (31)
Neurodegenerative disease (617)
Neuropsychiatric disorders (150)
Neuroscience (4248)
Neurotech (4)
NextGen: Class of 2026 (7435)
Non-profit (5147)
Now hiring (94)
Obesity (992)
Opinion (406)
Ovarian cancer (296)
Pain (347)
Pancreatic cancer (447)
Parkinson's disease (482)
Partnered (48)
Patents (787)
Patient advocacy (5)
Patient recruitment (981)
Patient selection (97)
Peanut (76)
People (66588)
Peptides (30)
Pharmaceutical (52)
Pharmacy benefit managers (42)
Phase 1 (23773)
Phase 2 (33740)
Phase 3 (25590)
Pipeline (13769)
Policy (421)
Postmarket research (3034)
Preclinical (9980)
Press Release (74)
Prostate cancer (405)
Psychedelics (94)
Radioligand (3)
Radiopharmaceuticals (439)
Rare diseases (1569)
Real estate (6675)
Recruiting (83)
Regenerative medicine (29)
Regulatory (29358)
Reports (76)
Research institute (2792)
Resumes & cover letters (546)
Rett syndrome (59)
RNA editing (38)
RSV (105)
Schizophrenia (224)
Series A (402)
Series B (277)
Service/supplier (8)
Sickle cell disease (142)
Special edition (35)
Spinal muscular atrophy (195)
Sponsored (61)
Startups (4017)
State (2)
Stem cells (6)
Stomach cancer (24)
Substance use disorders (22)
Supply chain (166)
Switzerland (9)
Tariffs (107)
Tax incentives (1)
The Weekly (160)
Vaccines (1418)
Venture capital (172)
Weight loss (663)
Wet AMD (6)
Women's health (187)
Women in leadership (1)
Worklife (28)
Date
Last 7 days (834)
Last 30 days (2931)
Last 365 days (32928)
2026 (27669)
2025 (31985)
2024 (36981)
2023 (42108)
2022 (53463)
2021 (58158)
2020 (57137)
2019 (50842)
2018 (38710)
2017 (35958)
2016 (35741)
2015 (41233)
2014 (33926)
2013 (29402)
2012 (31132)
2011 (31660)
2010 (29836)
Location
Africa (1118)
Alabama (116)
Alaska (7)
Arizona (426)
Arkansas (17)
Asia (47532)
Australia (8255)
California (16481)
Canada (4600)
China (1995)
Colorado (725)
Connecticut (744)
Delaware (521)
Europe (110535)
Florida (2544)
Georgia (539)
Hawaii (5)
Idaho (70)
Illinois (1379)
India (148)
Indiana (768)
Iowa (35)
Japan (759)
Kansas (155)
Kentucky (63)
Louisiana (67)
Maine (92)
Maryland (1955)
Massachusetts (11917)
Michigan (456)
Minnesota (909)
Mississippi (8)
Missouri (185)
Montana (36)
Nebraska (30)
Nevada (192)
New Hampshire (92)
New Jersey (4364)
New Mexico (37)
New York (4333)
North Carolina (2116)
North Dakota (13)
Northern California (8457)
Ohio (526)
Oklahoma (32)
Oregon (51)
Pennsylvania (3168)
Puerto Rico (37)
Rhode Island (63)
South America (1482)
South Carolina (104)
South Dakota (2)
Southern California (6597)
Tennessee (275)
Texas (2743)
United States (58513)
Utah (492)
Vermont (2)
Virginia (431)
Washington D.C. (87)
Washington State (1328)
West Virginia (4)
Wisconsin (184)
Wyoming (6)
801,355 Results for "pharmacia corporation merged with pfizer now operates as pfizer".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins
After Pfizer’s venture arm co-led Enodia Therapeutics’ $25 million seed round in January, the pharma has signed up to collaborate with the biotech on small-molecule drugs to eliminate pathogenic proteins where they’re being made.
October 13, 2026
·
2 min read
·
Tristan Manalac
Vaccines
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.
October 5, 2026
·
2 min read
·
Annalee Armstrong
Antibody-drug conjugate (ADC)
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of the pharma.
September 4, 2026
·
2 min read
·
Tristan Manalac
Earnings
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
Asked on a second quarter earnings call if Pfizer could direct more money to M&A amid a feeding frenzy across the pharma industry, CEO Albert Bourla defended his strategy.
August 4, 2026
·
1 min read
·
Annalee Armstrong
Antibody-drug conjugate
Pfizer scraps Seagen-developed ADC for solid tumors
Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.
July 15, 2026
·
1 min read
·
Gabrielle Masson
Press Releases
Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
October 4, 2026
·
19 min read
Press Releases
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
October 7, 2026
·
17 min read
Cardiovascular disease
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.
May 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
October 26, 2026
·
20 min read
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the U.S. last year.
April 29, 2026
·
2 min read
·
Nick Paul Taylor
1 of 80,136
Next
